No adverse events were reported in a dose-finding study conducted among patients whose bladders were instilled with twice the recommended concentration (dose) of solution of Cysview (hexaminolevulinate hydrochloride intravesical solution) .


Cysview (hexaminolevulinate hydrochloride intravesical solution) is contraindicated in patients with:

  • porphyria
  • gross hematuria
  • BCG immunotherapy or intravesical chemotherapy within the past 90 days
  • known hypersensitivity to hexaminolevulinate or any derivative of aminolevulinic acid

Last reviewed on RxList: 6/29/2010
This monograph has been modified to include the generic and brand name in many instances.


Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Women's Health

Find out what women really need.